BioSpace News Archive

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Intelligencia AI , a provider of AI-powered solutions that support data-driven decision-making in drug development, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,948,667 on April 2, 2024. The patent titled, “System and Interfaces for Processing and Interacting With Clinical Data,” pertains to the company’s novel techniques for training and leveraging a machine learning (ML) model to predict th

Convergent Therapeutics Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the investigational new drug (“IND”) application for CONV01-α, its lead candidate for the treatment of patients with advanced prostate cancer.

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced that, effective on April 1, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Fate Therapeutics, Inc. announced that on April 1, 2024 the Company granted restricted stock units representing 6,400 shares of its common stock to one newly-hired non-executive employee.

Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference, being held in a virtual format, April 8-11, 2024.

Sight Sciences, Inc. (Nasdaq: SGHT) announced today that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System (“OMNI”) and the TearCare System (“TearCare”), will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.

Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that it will report fourth quarter 2023 financial and operating results on Thursday, April 4, 2024, after the market close.

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.

Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE® Transcarotid Neuroprotection System PLUS (“NPS PLUS”), a key component of the TCAR® portfolio.